Filing summary
Important identity mismatch: The request identifies Processa Pharmaceuticals, Inc., but the supplied Form 10-K is for Heatwurx, Inc. It reports the fiscal year ended December 31, 2015—not a standalone fourth-quarter period. The summary below reflects the supplied filing and should not be attributed to Processa without verification.
Business context and reporting period
Heatwurx developed asphalt-repair equipment and a hot-in-place pavement recycling process. In 2015, it stopped operating its Dr. Pave service and franchise subsidiaries, substantially scaled back activity, and retained minimal operations to support one licensee, manage remaining equipment, and seek a merger or acquisition. The 10-K was signed and filed in June 2017.
Financial performance and condition
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $113,425 | $107,239 |
| Gross profit (loss) | $(12,451) | $40,406 |
| Loss from continuing operations | $(2,982,920) | $(3,685,601) |
| Net loss, including discontinued operations | $(3,354,227) | $(4,526,250) |
| Net cash used in operating activities | $(871,906) | $(2,691,638) |
Revenue rose slightly, but cost of goods sold exceeded revenue, producing a gross loss. Lower operating expenses and smaller impairment and financing-related charges helped reduce the total net loss year over year. Results included a $1,517,859 impairment of developed technology and a $186,068 impairment of assets held for sale; 2014 included an $822,205 loss on extinguishment of debt and a $390,659 goodwill impairment. No meaningful operating margin was reported; gross margin was negative in 2015.
At December 31, 2015, total assets were $104,321, total liabilities $2,083,128, and stockholders’ deficit $1,978,807. Cash was $2,090 in continuing operations plus $12,350 classified in discontinued operations. Contractual cash obligations totaled $1,597,341, all reported due in 2016: $947,361 of senior secured notes, $420,000 of unsecured notes, and a $229,980 revolving line of credit. Interest payable was $161,608. The company reported no available alternative financing and said it did not expect to meet scheduled principal payments.
Material changes, outlook, and risks
- Management discontinued Dr. Pave and Dr. Pave Worldwide, cut personnel and overhead, and reported no contracted revenue or immediate sales prospects. One licensee remained.
- Management stated that substantial doubt existed about the company’s ability to continue as a going concern. Its stated plan was to seek a merger or acquisition; absent a transaction, it expected to terminate operations.
- The company was in default on interest payments under secured notes and in default on the Dr. Pave revolving credit line. Secured lenders could call the debt or foreclose on collateral, including intellectual property. A subsequent-event disclosure says the secured notes were extended to September 30, 2016, but remained in default as of the filing.
- The independent auditor issued an unqualified opinion on the financial statements while highlighting substantial doubt about continued operations. Management found internal controls over financial reporting ineffective, citing insufficient accounting personnel; the reported material weakness was not remediated.
- Governance and reporting risks were significant: one person served as sole director and interim CEO/CFO, with disclosed ties to major lenders and investors. The filing also contains conflicting statements about voluntary Exchange Act reporting, including that the company chose to cease filing and that it had no plans to stop filing.
- The OTC share price declined materially during 2015; the filing warns of limited liquidity, potential dilution from outstanding warrants and options, and concentrated ownership.
Most important facts to verify
- Whether this Heatwurx filing is the intended filing; it does not identify Processa Pharmaceuticals.
- The exact reporting period and filing status, given the FY 2015 period, June 2017 filing date, and conflicting statements about reporting obligations.
- Current status and disposition of the secured notes, revolving line, lender defaults, and any foreclosure or debt conversion.
- Whether a merger or acquisition occurred, or operations were terminated, after the reporting date.
- The cash, debt, and discontinued-operations figures, including the distinction between continuing and discontinued operations.